Member Boards Experience Comradeship, Education at …a task force to study the public health consequences of re-stricted access policies and programs. Resolution No. 99-4-03 Title:

1S P E C I A L A N N U A L M E E T I N G I S S U E - 2 0 0 3

in this issue

8

23FDA Solicits Boards’ Assistance toFight Storefront Pharmacy Operations

(continued on page 3)

NABP Presents2003-2004 Executive Committee

3Meeting Delegates ApproveSix Resolutions, Two Defeated

N A T I O N A L A S S O C I A T I O N O F B O A R D S O F P H A R M A C Y

Member Boards Experience Comradeship, Education at Annual MeetingNew programs and interactive

sessions successfully created

an atmosphere of education

and networking at NABP’s 99th

Annual Meeting, themed

“Continuing Professional

Development: The Key to Your

Future,” May 3-7, 2003, at the

Philadelphia Marriott Hotel in

Philadelphia, PA. Member

boards of pharmacy not only

interacted with pharmacy

organizations, educators, and

industry representatives, but

they furthered their educa-

tional and professional growth

through continuing education

(CE) and special programs

focusing on today’s hot topics.

This year, NABP effectively

increased dialogue between its

members with two new program

opportunities. The presentation

of poster sessions, whereby

different boards of pharmacy

displayed current topics of

interest in the Educational

Presentation Area on May 3

and 4, stimulated discussions

about board issues. Participat-

ing boards included the Ari-

zona State board of Pharmacy,

Maine Board of Pharmacy,

Nebraska Board of Pharmacy,

New Mexico Board of Phar-

macy, North Carolina Board of

Pharmacy, North Dakota State

Board of Pharmacy, Virginia

Board of

Pharmacy, and

Washington

State Board of

Pharmacy.

Topics dis-

cussed included

telepharmacy,

delegated

dispensing,

small and

specialty

hospitals, and

labeling for

Hispanics. The other new

program item at the Annual

Meeting was the Meet the

Candidates Session. At this

time, voting delegates and

attendees were able to learn

more about those candidates

who ran for open positions on

the Executive Committee as

well as their opinions on

current issues.

The Annual Meeting also

featured the Association’s

annual business sessions.

During these sessions, meeting

attendees elected members and

officers to the Executive

Committee and discussed

resolutions proposed by the

districts and member boards.

Resolutions discussed included

limited access to prescription

medication programs, changing

role of pharmacists,

reimportation of medications,

easing pharmacist licensure

transfer requirements, federal

regulation of nutritional

supplements containing

ephedrine derivatives, continu-

ing professional development,

2Leaders Receive Honorsat Annual Awards Dinner

Attendees of NABP’s 99th Annual Meeting congregate in theEducational Presentation Area to network and share ideas.

A I D T O G O V E R N M E N T – T H E P R O F E S S I O N – T H E P U B L I C – 1 9 0 4 T O 2 0 0 3

V O L U M E 3 2 - S P E C I A L A N N U A L M E E T I N G I S S U E - 2 0 0 3

N A B P N E W S L E T T E R2

The NABP Newsletter(ISSN 0027-5700) is published 10 times

a year by the National Association ofBoards of Pharmacy (NABP) to educate,

to inform, and to communicate theobjectives and programs of the

Association and its 67 member boards ofpharmacy to the profession and the

public. The opinions and viewsexpressed in this publication do notnecessarily reflect the official views,opinions, or policies of NABP or any

board unless expressly so stated. Thesubscription rate is $35 per year.

National Association ofBoards of Pharmacy700 Busse Highway

Park Ridge, Illinois 60068 847/698-6227www.nabp.net

[email protected]

Carmen A. CatizoneExecutive Director/Secretary

Reneeta “Rene” RenganathanEditorial Manager

© 2003 National Association of Boards ofPharmacy. All rights reserved. No part of thispublication may be reproduced in any mannerwithout the written permission of the Executive

Director/Secretary of the National Association ofBoards of Pharmacy.

Leaders Receive Honors at Annual Awards DinnerDuring the Annual Awards

Dinner, held May 6, 2003, the

following individuals were

recognized for their tireless

efforts and dedication to NABP.

2002-2003 HonoraryPresident AwardHarold B. Sparr, who was

named 2002-2003 Honorary

President at last year’s meet-

ing, was honored this year.

Sparr has been actively in-

volved in many NABP commit-

tees and task forces

throughout the years, includ-

ing the Advisory Committee on

Examinations, Committee on

Resolutions, Committee on

Law Enforcement/Legislation,

the Task Force on Pharmacy

Technician Regulation, and the

Bureau of Voluntary Compli-

ance Advisory Committee.

Serving 40 years as an educator

and pharmacist in both

hospital and community

settings, Sparr retired from

practice in 2000. He has been a

member of the Massachusetts

Board of Registration in Phar-

macy since 1992 and in the

past has served as the Board’s

president. Sparr has been

recognized with several awards,

including the NABP Lester E.

Hosto Distinguished Service

Award and Wyeth Pharmaceuti-

cals’ Bowl of Hygeia Award from

the Massachusetts Pharmacists

Association.

2002-2003 President’s AwardPresident John A. Fiacco was

recognized for his achievements

during his term as NABP

president with the 2002-2003

President’s Award. With

Fiacco’s vision and support,

the Association has reached a

realm of better understanding

and support for and between

NABP’s member boards and

continues its progression to

becoming an international

leader in the area of pharmacy

law. During his presidency,

VIPPS Canada™ was estab-

lished; the Multistate Phar-

macy Jurisprudence

Examination® and the Elec-

tronic Licensure Transfer

Program™ saw expansion; and

the Pre-NAPLEX™ (a practice

examination for the North

American Pharmacist Licensure

Examination™) was launched.

A member of the New York

Board of Pharmacy, Fiacco is

also vice president of Central

Fill Pharmacy at Cardinal

Health in Dublin, OH.

2002-2003 Lester E. HostoDistinguished Service AwardsNABP’s Lester E. Hosto Distin-

guished Service Award is

presented to those individuals

whose contributions to the

protection of the public health

have, in the opinion of the

Executive Committee, signifi-

cantly furthered the goals and

objectives of the Association.

This year, two recipients were

named: Dyke F. Anderson and

Timothy J. Benedict. An

active member of the Nebraska

Board of Pharmacy from 1989

to 2002, Anderson contributed

an extraordinary amount of

time and energy to NABP. In

the past, Anderson served as

president, treasurer, and a

member of NABP’s Executive

Committee and was awarded

Wyeth Pharmaceuticals’ Bowl

of Hygeia Award in 2000. In

addition, he has played a role

in many committees and task

forces including the Committee


Incoming NABP President Donna S.Wall presents Dyke F. Anderson,past president of NABP and formermember of the Nebraska Board ofPharmacy, with the 2002-2003Lester E. Hosto DistinguishedService Award.


Member Boards Experience Comradeship, Education at Annual Meeting

Meeting Delegates Approve Six Resolutions, Two Defeated

changing NABP’s name, and

mandating continuing educa-

tion on medication safety.

Attendees were able to earn up

to six and a half hours of

American Council on Pharma-

ceutical Education (ACPE)-

approved CE credit on

programs including Continuing

Professional Development, the

new security regulations

stemming from the Health

Insurance Portability and

Accountability Act of 1996

(HIPAA), medication error data

review, the regulation of listed

chemicals, the return and

reuse of medications in long-

term care settings, substance

abuse treatment, and recent

regulatory cases heard by

professional boards. Meeting

participants had the option to

choose from CE sessions in

three programming tracks

targeting board of pharmacy

executive officers and members,

compliance staff, and phar-

macy practice issues.

Exciting discussions included

the accreditation equivalency

of Canadian pharmacy pro-

grams led by the ACPE and an

update on foreign medications

that was led by representa-

tives of Food and Drug

Administration.

Familiar sessions were the

Public Board Member Session

and the New Member Seminar,

with the first session providing

a place for public members to

meet and discuss topics of

interest and the second acting

as a forum for newly elected

executive directors and/or

representatives of the member

boards of pharmacy to gain a

deeper understanding of the

Association’s programs and

services.

Delegates from the member

boards of pharmacy adopted six

resolutions during NABP’s 99th

Annual Meeting. The resolu-

tions addressed such timely

issues as the changing role of

pharmacists, Continuing

Professional Development,

federal regulation of nutri-

tional supplements containing

ephedrine derivatives, limited

access to prescription medica-

tion programs, and

reimportation of medications.

The resolutions have been

forwarded to NABP’s Executive

Committee for review.

Resolution No. 99-3-03Title: Limited Access to

Prescription Medications

Action: Passed

Whereas, NABP recognizes the

importance of all US citizens

having access to medications; and

Whereas, access is sometimes

limited by manufacturers

through limited distribution

policies; and

Whereas, limited access

programs and policies can

place patients at risk from

beginning, continuing, or

completing their medication

therapy;

Therefore Be It Resolved that

the NABP Executive Committee

in collaboration with the Food

and Drug Administration (FDA)

and the Pharmaceutical

Research and Manufacturers of

America (PhRMA) commission

a task force to study the public

health consequences of re-

stricted access policies and

programs.

Resolution No. 99-4-03Title: Changing Role of

Pharmacists

Action: Passed

Whereas, the role of the

pharmacist continues to evolve

from a product-based practice

to one that places the empha-

sis on patient care; and

Whereas, NABP’s Regulating

for Outcomes Project recog-

nizes the ability and responsi-

bility of the pharmacist to

render pharmaceutical care; and

Whereas, an understanding of

the abilities and responsibili-

ties of the pharmacist by

legislators and the public will

greatly enhance public health;


NABP continue its efforts to

assist state boards of phar-

macy, state and national

pharmacy organizations, and

public relations efforts to

educate the public at large and

(continued from page 1)



Presented by NABP’s 2002-2003

Chairman Richard K. “Mick”

Markuson

Good afternoon.

Six years ago I

began my tenure

on the Executive

Committee. Today

I stand before you

for a final time as

chair of the NABP

Executive Com-

mittee. Although my experi-

ences with NABP and the Idaho

Board of Pharmacy date back

to 1985, when I was first

appointed to the Idaho Board

of Pharmacy, the past six years

have been some of the best

times of mine and Ruth’s lives.

Just the other day I was

talking to my daughter, Karen,

and her husband, Matt, who

are stationed in Italy as

members of our armed forces.

She mentioned to me how this

would be the first NABP

meeting she and Matt would be

missing in some time. She

asked me to thank all of you

for the kindness extended to

them. Talking with Karen

reminded me of when I stood

before you at the 98th Annual

Meeting in Phoenix. I spoke of

the heroes of September 11 and

how important it was to have

heroes to look up to and model

one’s life after. I now think

about the heroes who are

fighting in Iraq and Afghani-

stan to liberate the people of

Iraq and protect the US from

future attacks and harm. I

hope that we never forget them

or forget about the need to

identify heroes in our lives and

ascribe to fight for what we

believe is right.

Report of the Executive CommitteeMy years at NABP have honed

this lesson well. Although our

fights for the protection of the

public health are far less

dramatic than the present

conflicts around the world,

they are still important. A

prime example of how NABP

strives to protect the safety and

welfare of the public is the

Verified Internet Pharmacy

Practice Sites™ (VIPPS®) pro-

gram that was developed in

response to public and regula-

tory agency concerns regarding

the safety of Internet pharmacy

practice. VIPPS is one of the

best and brightest of NABP’s

programs. Consumers looking

to purchase prescriptions

online can be assured that, if

VIPPS-certified, a site is able to

appropriately dispense pharma-

ceuticals to the public, is

licensed in good standing by

applicable state boards of

pharmacy, has met a rigorous

criteria review, and successfully

completed an on-site inspec-

tion. Consumers can also be

confident that the medications

they receive are products

approved by the Food and Drug

Administration (FDA).

Until now, Canadians did not

have the same assurances

when making online prescrip-

tion decisions. In January that

changed. NABP and our

colleague to the North, the

National Association of Phar-

macy Regulatory Authorities

(NAPRA), are jointly launching

VIPPS Canada™. Once again,

NAPRA, whose leadership in

Canada is unparalleled, is an

integral component of the

success of this program. We are

proud to assist Barbara Wells

and the NAPRA leadership in

this project and learn from

NAPRA’s other accomplish-

ments. Through the VIPPS

Canada program, Canadian

residents can recognize legiti-

mately operating Internet

pharmacies that have met the

stringent standards of the

VIPPS Canada program. To be

eligible for VIPPS Canada

certification, pharmacies must,

among other requirements,

comply with the laws of the

jurisdictions where they

operate. Canadian pharmacies

that ship prescription medica-

tions into the United States, in

violation of US law, are not

eligible for Canadian or US

VIPPS certification. NAPRA

expects to begin accepting

applications and award the

first VIPPS Canada seal in the

next few months.

While gaining momentum in

the International arena, the

VIPPS program also continues

to expand in the United States.

In February 2003, NABP staff

met with the American Asso-

ciation of Veterinary State

Boards (AAVSB) to discuss

jointly developing a Veterinary

VIPPS program. AAVSB and

NABP signed a memorandum of

understanding to explore

expanding the VIPPS program

to include veterinary pharma-

cies. And in March 2003, NABP

executed its first co-branding

contract permitting Tel-Drug,

Inc, to use the VIPPS Seal on

Tel-Drug’s www.Discount

PrescriptionCenter.com Web

site. In order to display the

VIPPS Seal, interested co-

branded or subsidiary Web sites

need to provide information


and documentation about the

co-branded site, including its

relationship with the VIPPS-

certified pharmacy, and, once

approved, sign a licensing

agreement. This expansion of

the VIPPS program increases

information and guidance for

the public. It also helps NABP to

promote the VIPPS program and

provide greater recognition for

the VIPPS-certified pharmacies.

It has been said that imitation

is the highest form of flattery.

NABP is aware of other pro-

grams that claim or represent

to the public some degree of

Internet “accreditation” or

“verification.” Some of those

programs indicate that their

processes are modeled after the

VIPPS program. Ironically, we

don’t believe this to be the

case, particularly when such

sites award seals to Internet

pharmacies that operate

illegally. At least one of these

alternate programs plans to

accredit US, Mexican, and

Canadian Internet and mail-

order pharmacies that operate

or ship medications to the

United States in contravention

to federal and state law pro-

vided the appropriate fee is

paid to the “recognition”

service. In NABP’s opinion,

these programs intentionally

undermine regulatory efforts by

recommending that consumers

purchase medications from

unlawfully operating pharma-

cies, in complete disregard for

consumers’ health and welfare.

To counter the efforts of these

self-promotion groups, NABP is

increasing its consumer

outreach and educational

initiatives and forwarded to the

state boards of pharmacy lists

of suspiciously operating Web

sites that offer to illegally ship

prescription medications to the

US. NABP plans to regularly

update the boards as new Web

sites are discovered.

Without a doubt, the VIPPS

program remains the sole

beacon for patient safety in

that it is the only online

pharmacy certification program

that accredits legitimately

operating Internet pharmacies

through a valid accreditation

process that includes license

verification and on-site inspec-

tions. Moreover, NABP staff is

currently evaluating the

feasibility of expanding the

VIPPS program to certify

legitimate mail-order pharma-

cies. Details of the proposed

expansion should be finalized

within a few short months.

We’ll keep you informed as the

details unfold.

The VIPPS program is not the

only area at NABP that could

see some changes. This year, the

membership will vote on

proposed amendments to the

Constitution and Bylaws and

hear additional amendments

that will be voted upon at next

year’s 100th Annual Meeting in

Chicago, IL. To assist you in

understanding the proposed

amendments, I want to briefly

summarize each proposal. We’ve

included a summary of each

proposed amendment as well as

the exact wording of each after

tab five in your Annual Meeting

Programming Book.

Let’s begin with the proposed

amendment submitted by the

Nevada State Board of Phar-

macy that will be voted upon

during this session. The

outcome of this vote deter-

mines the open positions for

this year’s Executive Commit-

tee (EC) election. This proposal

provides for an expansion of

the EC from 10 to 14 members

(10 member and four officer

positions), with the member

positions consisting of one

pharmacist member from each

of the eight districts, one at-

large pharmacist member, and

one at-large public member. If

the Nevada proposal fails, the

structure of the EC remains as

it is currently.

Being read at this Annual

Meeting and voted on at next

year’s Annual Meeting is a

proposal submitted by the

Virginia Board of Pharmacy.

This proposal contains amend-

ments to the Constitution that

would affect the composition of

the Executive Committee. It

would add two more member

positions to the EC with each

position representing one of

NABP’s eight districts. Other

terms of this amendment

provide for EC member elec-

tions at the district level by

district member boards, reduce

the EC member term of office

from three to two years, and

eliminate the Nominating

Committee.

In addition to Virginia, the

Executive Committee this year

proposed amendments to both

the Constitution and Bylaws.

Of the five sets of EC’s pro-

posed amendments to the

Constitution, the majority of

the changes are non-substan-

tive edits to update the Consti-



The NABP Annual

Meeting has

always been a

special time for

me. This meeting

marks my tenth

Annual Meeting

and marks the

end of my term as

your president and the culmi-

nation of a year of serving as

your chief elected officer. It

marks the end of a year of

cross-country travel where I

met many of the members of

our Association and many of

the leaders of pharmacy. When

I stood before you last year in

Phoenix, I shared with you my

thoughts on the future of NABP.

In preparing that speech, I soon

realized that every time I tried

to envision what the future

would offer, I was reminded of

the past and the contributions

of past NABP members and

presidents. Today, those same

thoughts hold true. We owe so

much to those who came before

us and we have a responsibility

to do our best to improve the

present for those who will come

after us.

I also realize how fortunate I

was to serve as your president

and represent NABP in a

variety of meetings and confer-

ences this past year. My

experiences reinforced to me

the important place NABP

holds within American phar-

macy. The realization of that

importance rang through as I

traveled from my home state of

New York. From Providence, RI,

to Coeur D’Alene, ID. From

Harrisburg, PA, to St Louis,

President’s AddressMO, and from Louisville, KY, to

the limits of civilization in

Medora, ND! NABP, while not

without challenges, is vibrant,

strong, and growing and is one

of the leading voices in the

profession of pharmacy today.

In my Presidential Address last

year I spoke about the need to

improve the Foreign Pharmacy

Graduate Examination Com-

mittee™ (FPGEC®) process. At

that time we were in a crisis

situation. Our staff was

overwhelmed with the number

of applications, and as a result

of that unbelievable workload,

the processing of applications

was significantly delayed.

NABP’s customer service to

applicants fell well below the

standard we set and maintain

in all of our programs. We were

not pleased with the service we

were providing and we were

determined to make changes

that would allow us to achieve

NABP’s customer service

standards. We set that as a

high priority and immediately

increased staffing and started

analyzing our processing

procedures, looking to elimi-

nate unnecessary delays.

Unfortunately, just as our

efforts began we uncovered the

compromise of the Foreign

Pharmacy Graduate Equiva-

lency Examination® (FPGEE®).

Needless to say, everything

came to a grinding halt as we

focused all of our efforts on

identifying the compromise and

securing the FPGEE program.

In Jack Atkinson’s written

Report of Counsel, he will

provide an in-depth analysis of

that situation and update you

on the investigation that is

still ongoing. A copy of his

report, as well as Mick’s and

Carmen’s, will be available at

the registration desk immedi-

ately following this session.

Jack will also discuss his

report during the Open Mike

Session. Although the compro-

mise significantly impacted

NABP’s operations, it was one

of those “every dark cloud has

a silver lining” situations. The

compromise of secure items

required the immediate cessa-

tion of test administrations.

Recognizing that time would be

needed to investigate the

compromise before test admin-

istrations could begin again,

we launched a two prong effort

to restore the program. The

NABP Examination Security

Group initiated its response

strategies and began to unravel

the tenets of the compromise.

Simultaneously, an operational

team began to focus on the

processing of applications,

employing more efficient

procedures. To support the

rebuilding efforts, we deployed

additional staff to the FPGEC

program from other depart-

ments. During this hectic time

we set two goals for those

operations: first, isolate the

compromise, secure the exam,

and have a new exam ready for

administration by June 2003;

and, second, process all

applications currently in the

system and maintain a three-

to four-week processing time

for all new applications. I am

pleased to report that we have

achieved our first goal and we

are close to achieving the

second. Although we anticipate

some bumps in the road, the


President John A. Fiacco

Larr

y S

ale

se P

hot

o Ph

ila.


FPGEC Program is on track,

secure, and better than ever.

We owe a debt of gratitude to

the members of the FPGEC

Review Committee for their

response to this crisis. Instead

of asking “why” when advised

of the situation and the need

for a new exam, they responded

with “Let’s get it done!” I would

like to personally recognize all

of those individuals here today

and ask that if you know them

or have occasion to meet with

them that you extend our

thanks on behalf of NABP.

Those individuals are: Louis

Ace, Jr, Charles Barfknecht,

John Block, Stephen Dahl,

William Garnett, Keith

Guillory, Boka Hadzija,

Monina Lahoz, Holly Mason,

Ralph Raasch, Timothy Smith,

Sister Margaret Wright, Dale

Wurster, Jr, and David

Zgarrick.

While still on the subject of

FPGEC, last year I spoke about

the globalization of NABP with

an eye toward making our

testing platforms available in

countries overseas. I guess you

could say we achieved global-

ization, but certainly not quite

the way I had envisioned. The

events of last year demon-

strated that we cannot yet

confidently administer tests

outside the country. After

careful consideration, the

Advisory Committee on Exami-

nations and Executive Com-

mittee have decided that

overseas testing is not an

option that NABP can offer at

this time. It is an idea and

service that will eventually be

offered because, as Jerry Moore

mentioned in his report last

year, our society is a global

society and NABP an interna-

tional organization whose

programs and services extend

and will soon expand beyond

the present borders of the

United States. As we move

forward with globalization,

NABP will be prepared to offer

services such as overseas

testing, but the time is not

right now.

Pre-NAPLEXA new service whose time has

come is NABP’s offering of a

self-assessment tool for

candidates preparing to take

the North American Pharmacist

Licensure Examination™

(NAPLEX®). The Pre-NAPLEX™

is revolutionary for NABP

because it introduces Internet-

based testing. The Pre-NAPLEX

is designed to familiarize

students with the NAPLEX

testing experience and is

similar to the actual NAPLEX

in many ways. Students who

take the Pre-NAPLEX will have

the chance to “preview” the

touch and feel of the NAPLEX

computer experience as they

are being challenged by actual

retired NAPLEX questions. Like

other practice examinations, a

student’s score on the Pre-

NAPLEX should be similar to

what they can expect to receive

on the NAPLEX, but may not

be the actual score attained,

nor is it a guarantee of passing

the actual examination. The

Pre-NAPLEX is just the begin-

ning of NABP’s movement into

the area of Internet testing and

self-assessment.

The Pre-NAPLEX is evidence of

NABP’s adaptability and

responsiveness to the changing

environment and our ability to

utilize the valuable data

resources that we possess.

Data ManagementHarvesting and managing

NABP’s data resources was

another one of the goals I

established for my year as

president. To that end, a task

force was organized to study

the issue and report its recom-

mendations to the Executive

Committee. The task force did

an outstanding job and offered

the following recommendations

to the Executive Committee:

n serve as the central source

of information;

n survey potential customers

and inquire what they

would pay for valuable

information;

n provide a search and access

tool for customers to search

by topic;

n hold a series of focus

groups, possibly at NABP’s

Annual Meeting or district

meetings, for further input

and support; and

n look at other sources to

continue to build the data

collection and information

sharing, such as Federation

of Medical Board Examiners

and the Office of the

Inspector General.

The Executive Committee

accepted those recommenda-

tions and commissioned a

complete rebuilding of the

operations and data manage-

ment systems within NABP.

Code named Project Infinity,

the transformation in NABP



Delegates attending the NABP’s

99th Annual Meeting elected

individuals to fill the presi-

dent-elect, treasurer, and open

member positions on the

Association’s 2003-2004

Executive Committee (EC).

At the conclusion of the

Annual Meeting, President-

elect Donna S. Wall, a member

of the Indiana Board of Phar-

macy, assumed the position of

NABP president, and immediate

Past President John A. Fiacco,

a member of the New York

Board of Pharmacy, became the

chairman of the EC.

The newly elected officers for

NABP are President-elect Donna

M. Horn, who is president of the

Massachusetts Board of Regis-

tration in Pharmacy, and

Treasurer Dennis K. McAllister,

vice president of the Arizona

State Board of Pharmacy. Oren

M. Peacock, Jr, treasurer of the

Texas State Board of Pharmacy,

and Oregon State Board of

Pharmacy Executive Director

Gary A. Schnabel were each

elected to serve a three-year

member term on the EC. Also

elected this year was New York

Board of Pharmacy Executive

Secretary Lawrence H.

Mokhiber, who will be serving a

one-year term as member-at-

large. The other members of the

2003-2004 NABP EC who are

currently fulfilling their terms

are Howard C. Anderson, Jr,

executive director of the North

Dakota State Board of Phar-

macy; Michael A. Moné, execu-

tive director of the Kentucky

Board of Pharmacy; and Charles

R. Young, executive director of

the Massachusetts Board of

Registration in Pharmacy.

NABP Presents 2003-2004 Executive Committee

Abbreviated biographies for

the officers and members of

the Association’s 2003-2004

EC follow:

Chairman: John A. Fiacco, RPhJohn A. Fiacco, a member of

the New York Board of Phar-

macy (District II), assumed his

position as chairman of the

NABP EC after completing one-

year terms as both president

and president-elect. Fiacco also

served one year as NABP

treasurer and as a member of

the EC. A member of the

Multistate Pharmacy Jurispru-

dence Examination® Review

Committee since its inception

in 1997, he also chaired

NABP’s Committee on Resolu-

tions in 1997 and 1998. A

graduate of the Albany School

of Pharmacy, Albany, NY,

Fiacco is vice president of

Central Fill Pharmacy with

Cardinal Health in Dublin, OH.

President: Donna S. Wall, PharmDDonna S. Wall, a member of

the Indiana Board of Pharmacy

(District IV), automatically

assumed the position of presi-

dent after completing her one-

year term as president-elect. At

the conclusion of her year as

president, she will assume the

chair position of the NABP EC.

Wall is the past treasurer of the

Association and also served two

years as a member of the EC.

She has been an active partici-

pant on various Association

task forces. She is currently a

clinical pharmacist for the

Adult Critical Care unit at

Indiana University Hospital,

Clarian Health Partners. Wall

received her Bachelor of Science

in pharmacy degree from Butler

University College of Pharmacy

and her PharmD from Purdue

University School of Pharmacy.

President-elect: Donna M. Horn, RPhDonna M. Horn, president of

the Massachusetts Board of

Registration in Pharmacy

(District I), was appointed

president-elect during the

Association’s 99th Annual

Meeting. She assumed this

position following a one-year

term as NABP treasurer and

two three-year terms on the

EC. Horn was the EC liaison to

numerous task forces. She is

the manager of regulatory

NABP 2003-2004 Executive Committee: (from left, standing) Michael A.Moné, Gary A. Schnabel, Howard C. Anderson, Jr, Charles R. Young, OrenM. Peacock, Jr, Lawrence H. Mokhiber, (from left, seated) John A. Fiacco,Donna S. Wall, Donna M. Horn, and Dennis K. McAllister.

Larr

y S

ale

se P

hot

o Ph

ila.


affairs for Brooks Pharmacy.

Horn earned her pharmacy

degree from the Massachusetts

College of Pharmacy and

Health Sciences.

Treasurer: Dennis K. McAllister, RPhDennis K. McAllister, vice

president of the Arizona State

Board of Pharmacy, was elected

NABP treasurer. Prior to his

election he was a member of

the NABP EC. From District

VIII, he is the assistant dean for

Pre-Doctoral Affairs at Midwest-

ern University, Glendale College

of Pharmacy. McAllister earned

a bachelor of science degree in

pharmacy from the University of

Minnesota.

Executive Committee Member:Howard C. Anderson, Jr, RPhHoward C. Anderson, Jr,

executive director of the North

Dakota State Board of Phar-

macy (District V), is serving the

third year of a three-year

member term on the NABP EC.

An active participant on

committees and task forces, he

is also the recipient of several

awards including Wyeth

Pharmaceuticals’ Bowl of

Hygeia Award, the Al Doerr

Service Award, and the North

Dakota Society of Health-

System Pharmacists Pharma-

cist of the Year award.

Anderson earned a bachelor of

science degree in pharmacy

from the North Dakota State

University College of Pharmacy.

Executive Committee Member:Michael A. Moné, RPh, JDMichael A. Moné, executive

director of the Kentucky Board

of Pharmacy (District III), is

serving the second year of a

three-year term as a member of

the NABP EC. Prior to his

tenure with the Kentucky

Board, he was the assistant

attorney general at the Florida

Attorney General’s office. In

addition to serving on numer-

ous NABP committees and task

forces, Moné served as the

speaker of the American

Pharmaceutical Association

House of Delegates. Moné

graduated from the University

of Florida College of Law and

the University of Florida

College of Pharmacy.

Executive Committee Member:Oren M. Peacock, Jr, RPhOren M. Peacock, Jr, treasurer

of the Texas State Board of

Pharmacy (District VI), was

elected to a three-year term as

a member of the NABP EC.

Peacock has served on the

Texas Board since 1999. As a

member of NABP, he has served

on several task forces and

committees including the Task

Force on Centralized Prescrip-

tion Filling, the Task Force on

Evaluation and Modification of

NABP’s Constitution and

Bylaws, and the Committee on

Resolutions. He earned his

pharmacy degree from the

University of Texas and cur-

rently serves as vice president

of pharmacy relations at

Eckerd Corporation.

Executive Committee Member:Gary A. Schnabel, RPh, RNGary A. Schnabel, Oregon State

Board of Pharmacy (District VII)

executive director, was elected

to a three-year term as a

member of the NABP EC.

Schnabel was named executive

director of the Oregon Board in

1999. An active member of the

Oregon Board, Schnabel has

also served on committees for

NABP including the Constitu-

tion and Bylaws Committee

and Nominating Committee.

He earned his pharmacy degree

from Oregon State University

in 1985.

Executive Committee Member:Charles R. Young, MS, RPh, CFECharles R. Young, executive

director of the Massachusetts

Board of Registration in

Pharmacy (District I), is serving

the second year of a three-year

term on the EC. Young began

his tenure with the Massachu-

setts Board in 1985 as a

compliance agent. He assumed

the position of executive

director in 1997. He earned his

pharmacy degree from the

Massachusetts College of

Pharmacy and Health Sciences.

Executive Committee Member-at-Large: Lawrence H. Mokhiber, MS, RPhLawrence H. Mokhiber, New

York Board of Pharmacy

(District II) executive secretary,

was elected to a one-year term

as member-at-large. Mokhiber

has served as executive secre-

tary for the New York Board

since 1987. He also serves as

the executive secretary for the

New York State Board of

Midwifery. Mokhiber chaired

NABP’s Advisory Committee on

Examinations from 1993 to

1994 and from 2001 to 2002,

and has served on the National

Association of Boards of

Pharmacy Licensure Examina-

tion® Review Committee. He

earned his pharmacy degree

from Albany College of Phar-

macy in 1971.


Good afternoon,

ladies and

gentlemen.

What a privilege

it is to stand

before you as

your 99th

president. That

distinction is

somewhat of an overwhelming

title, 99th president of NABP. It

immediately makes me feel

much older than I am and

disappointed that I won’t be

the one to stand before you as

the 100th president!

Well, I think I may be in a more

enviable position than the

100th president because I have

the opportunity to set the stage

for our Centennial Celebration

and then sit back with my 99th

president ribbon and enjoy the

festivities. And what festivities

there will be!

There are many things that we

share through our membership

within NABP: our concern for

the protection of the public

health, our support of NABP,

and our dedication as pharma-

cists to the patients we serve.

My career outside of NABP is as

a clinical pharmacist in a

tertiary care center (and, to

brag a little), the institution

that helped Tour de France

superstar Lance Armstrong

successfully manage his

testicular cancer and go on to

be one of history’s greatest

competitors. My practice

provides me with the opportu-

nity to interact with patients

in a meaningful and clinical

manner. The interactions with

Remarks of the Incoming Presidentpatients helps to affirm that, as

a board member and practicing

pharmacist, the patient is

paramount to me and the

highest priority of my agenda

as your president this year.

No Patient Should beLeft BehindI know that NABP’s involve-

ment in practice issues must

be balanced with the responsi-

bility to support the day-to-day

activities of the state boards of

pharmacy. However, it has been

my experience that at NABP we

are able to balance these two

objectives and integrate them

well in all that we do. Our

committee recommendations,

programs, and services have

always focused [on], or main-

tained as critical determinants,

improving the health and

welfare of the patient. One of

the primary messages I want to

carry as your president and

incorporate in all that NABP

accomplishes over the next

year is that we must ensure

that “No patient is left behind!”

As pharmacists and board

members we struggle every day

to balance patient care with

patient needs in a system that

sometimes determines the best

care for a patient based upon

the assigned reimbursement or

insurance coverage limitations.

Unfortunately, in an environ-

ment where the bottom line is

the deciding factor, patient

safety factors like education

and monitoring are often

discarded. These constraints of

the system lead us to ask

ourselves what we can do as

pharmacists and board mem-

bers to change the environment

and improve care. Some people

would look to us as boards of

pharmacy to mandate better

care or remove the financial

road blocks from the system. In

my experience as a member of

the Indiana Board of Phar-

macy, it appears to me that

mandating responsibilities

works only to a certain extent

in motivating pharmacists to

provide the type of care that

should be provided. It has also

been my experience that trying

to resolve financial problems

with regulation often causes

more problems than existed

initially.

One example that immediately

comes to mind of where

mandating patient care may

not have worked as well as

intended is the effort to

mandate patient counseling

some years ago. At the time,

and today, it is clear that

counseling, supplemented by

the written information

provided with their medica-

tions, is both beneficial and

improves the medication use of

the patient. Mandating coun-

seling was a noble effort, but a

not-so-successful action.

Recently, a board member from

another state that mandated

counseling to all patients told

me, “If every pharmacist who

didn’t counsel a patient at

some time was placed on

probation, every pharmacist in

the state would be on proba-

tion.” Why does this happen?

The reasons are numerous and

we all know what they are. We

have many patients who don’t

see the necessity of counseling

because, as pharmacists and

board members, we have not


President-elect Donna S. Wall

Larr

y S

ale

se P

hot

o Ph

ila.


helped them to understand its

value to their health, safety,

and well-being and, thus,

demand counseling.

We have too many patients

who can’t comprehend what

the pharmacist is telling them,

perhaps because they are

overloaded with other news or

possibly have very real prob-

lems with literacy and language

barriers. Most disturbing to me

are those pharmacists who do

not want to provide, or do not

feel competent to provide,

patient-specific counseling.

These needed services are also

being acknowledged and

requested by other health care

professionals. The April 17,

2003 issue of the New England

Journal of Medicine, one of the

most respected medical jour-

nals in the world, had an

editorial titled “Adverse Outpa-

tient Drug Events – A Problem

and an Opportunity.” The

editorial by Dr William M.

Tierney stated the following:

“Pharmacists should routinely

inquire about drug-specific and

nonspecific symptoms, instead

of merely asking patients ‘Do

you have any questions?’ In

addition pharmacists and

physicians should collaborate

to improve pharmacotherapy.”

The New England Journal of

Medicine has an editorial

asking pharmacists to talk to

their patients. This editorial

brings about mixed emotions

for me. On one hand, the

profession is vindicated and

acknowledged that we make a

huge difference in patient care

and, yet, on the other hand,

we have physicians who are

having to remind us “in a very

public manner” that we are not

doing what we can for our

patients’ safety.

But rather than list the

excuses and resolve ourselves

that the obstacles to change

are insurmountable, we should

ask, how do we change this

situation? How do we change

patient expectations as board

members and pharmacists?

How do we motivate pharma-

cists to provide these patient

care services? How do we

change the practice model to

that of one that puts the

patient’s safety and care above

all other aspects of the profes-

sion of pharmacy?

The answers to those questions

are not that difficult to find.

Since pharmacists first crushed

and mixed powders into elegant

dosage forms our message to

patients was to expect and

demand that the pharmacist

provide the right medication

ordered by the doctor. That

message set a standard for

dispensing medications that the

patient understood and ex-

pected every time that piece of

the paper was presented to the

white-coated pharmacist behind

the counter. It was a good

message and served our patients

well. But it was also a message

and standard for a different

time for health care and phar-

macy. However, the message for

pharmacy today needs to change

and set a new expectation from

our patients. That new expecta-

tion is that patients deserve to

receive the correct medication

and quality patient care services

from the health professional

best suited to deliver this care,

the pharmacist.

As boards of pharmacy sup-

porting this new expectation

and standard we need to

change our approach to

regulation. It will require us to

tackle issues and barriers,

economic and otherwise, which

have prevented pharmacists

from interacting with their

patients. Those issues include

one of the most frequent

complaints that I hear from

pharmacists when asked why

they do not engage in patient

care services, pharmacist

workload. Pharmacists inces-

santly note that they are too

busy and, therefore, forced to

choose or target only certain

patients for counseling and

patient care services. In today’s

health care system of multiple

disease states, treatments, and

medications, that sporadic and

unstructured approach does

not serve the patient well.

As president, I will ask the

Executive Committee to

support a task force to address

this issue and propose new

solutions to this age-old

problem. Additionally, NABP’s

new Continuing Professional

Development project, which

John Fiacco spoke about in his

remarks, will be a critical

factor within this process. I

believe that now is the time to

design regulatory incentives for

pharmacists to provide patient

care for reasons other than fear

of discipline.

Access to PatientInformationOne of the major hindrances

that pharmacists must over-

come in order to provide



Presented by NABP’s 2002-

2003 Treasurer Donna M. Horn

Growth,

strength, and

security. Those

are three words

not often

spoken during

a time when it’s

common to

hear about

corporate downsizing and

budget cutbacks.

But for NABP, those three

words describe 2002. Despite

the security breach of the

Foreign Pharmacy Graduate

Equivalency Examination®

(FPGEE®) and the creation of a

new paper-and-pencil exami-

nation, the Association was

able to maintain its financial

strength.

It’s that strength that allowed

NABP to set aside revenue from

2002 to develop the new

programs John [Fiacco] just

discussed, including the Pre-

NAPLEX™ and Continuing

Professional Development

programs, along with the

Project Infinity initiative.

During 2002, NABP’s revenue

grew by nearly 23% while

expenses increased by only

12%. This revenue increase is

due in part to the unprec-

edented increase in the num-

ber of candidates who sat for

the FPGEE and the record-

setting year of the Electronic

Licensure Transfer Program™

partly due to the addition of

Florida to the program. These

factors, combined with the

addition of four states to the

Multistate Pharmacy Jurispru-

dence Examination® program

Report of the Treasurerand the consistent contribution

of the North American Pharma-

cist Licensure Examination™

program, all contributed to

NABP’s revenue growth.

While all programs saw growth,

none compared to the Foreign

Pharmacy Graduate Examina-

tion Committee™ (FPGEC®)

certification program. More

than 1,700 candidates sat for

the FPGEE in 2002, compared

to 750 in 2001. We attribute

this dramatic increase to the

announcement made by the

Advisory Committee on Exami-

nations (ACE) and the Execu-

tive Committee that the

educational requirement for

qualification for the FPGEE,

and ultimately, FPGEC Certifi-

cation, would change from a

four-year degree to a five-year

degree program in pharmacy.

Although the change affects

foreign-educated pharmacists

who graduate on or after

January 1, 2003, it appears

that the foreign graduate

community believed that the

change applied to all appli-

cants. This misconception

coupled with a steady increase

in the number of foreign

graduates seeking licensure in

the US accounts for the growth

in the FPGEC program. NABP

received a record-setting 3,600

FPGEC applications in 2002

and 1,900 in 2001.

The 2002 Program Expenses

chart on the screen demon-

strates that examination

program expenses represent

66% of all of NABP’s expenses.

To break it down even further,

50% of all expenses are in-

curred just to provide the

programs, 9% of the expenses

maintain and update the

programs through item devel-

opment and review meetings,

standards setting, and content

analysis, and 3% of the ex-

penses are attributable to a

variety of program costs. In

addition, 4% of NABP’s ex-

penses are used in research

and development of new

programs and program en-

hancements. These expenses

remain consistent with 2001.

A major expense that NABP

incurs each year is the increase to

its examination program reserve

fund. In 2002, 10% of NABP’s

expenses went to increase the

exam reserve fund to $3.2 million.

This compares to 7% of 2001’s

expenses. The need for the exam

reserve fund was never as evident

as it was during the FPGEC

security breach. The exam reserve

fund was used to investigate the

breach, begin development of a

new examination, and put

everything in place for the June

2003 FPGEE administration.

Because of the reserve fund,

NABP was able to continue all of

the other programs without

Larr

y S

ale

se P

hot

o Ph

ila.

NABP’s increase inrevenue and ability to holdexpenses to a smallerincrease had a profoundimpact on the financialstrength of theAssociation.

– NABP 2002-2003Treasurer Donna M. Horn


interruption and without using

other valuable resources.

NABP’s increase in revenue

and ability to hold expenses to

a smaller increase had a

profound impact on the

financial strength of the

Association. Total assets

increased 20% during 2002.

This increase in total assets

was allocated between current

assets, long-term investments,

and segregated investments,

which is the examination

program reserve fund. There

were only minor additions to

the Association’s property,

furniture, and equipment. In

fact, after depreciation, prop-

erty, furniture, and equipment

show an overall decrease from

the prior year. The increase in

total assets will not be idle

capital. The revenue growth is

due to program growth, not

from increased fees. Continued

program growth and the

addition of new programs

create the need for increased

expenditures in property,

furniture, and equipment.

Recognizing these needs, NABP

has earmarked some of 2002’s

revenue for building replace-

ment, infrastructure updates,

and Project Infinity.

NABP’s net assets, which we

often refer to as reserves,

increased 21% to $8.4 million.

NABP’s 2003 Operating Budget

RevenueExamination and Licensure Programs $ 8,601,625

Survey Sponsor Fees 45,000

State Membership Dues 16,750

Publication Fees 15,400

Convention, Conference, Registrations, and Contributions 225,740

Investment Income 396,000

Grant Income 5,000

Affiliated Organization Reimbursements 186,100

Total Revenue $ 9,491,615

Operating ExpensesPurchases $ 163,480

Computer and Office Equipment; Building Renovation and Furniture

General and Administrative Expenses 5,132,825

Accounting/Audit Fees, Auto Lease, Building Maintenance,

Contributions, Copying, Depreciation, Electric, Equipment Rental

and Maintenance, Fringe Benefits, Insurance, Investment,

Legal Fees, Library, Memberships and Dues, Postage, Printing,

Public Relations, Retirement Plans, Salaries, Shipping, Supplies,

Telephone, Temporary Help, Utilities

Program Expenses 4,195,310

Centennial Annual Meeting, Conferences, Consulting, Convention

Program/Speaker Expense, Examination Insurance Reserve,

Honoraria, Photographs, Printing, Seminars, Testing Examination Fees

Total Operating Expenses $ 9,491,615

Expenses in Excess of Revenue $ -0-



legislative representatives

regarding the changing roles of

pharmacists, provision of

pharmaceutical care, and

regulating for outcomes.

Resolution No. 99-5-03Title: Reimportation of

Medications

Action: Passed

Whereas, an alarming and

increasing number of consum-

ers are purchasing medications

from sources outside of the US

to meet their prescription

needs and obtain these medica-

tions at lower prices than

available in the US; and

Whereas, this practice is in

violation of the law and

eliminates the physician,

pharmacist, patient relation-

ship and the opportunity for

meaningful pharmaceutical

care, thus detrimentally

affecting the protection

afforded patients; and

Whereas, NABP has expressed

its great concern of the detri-

mental effect of this practice on

the public health to the (1) US

Department of Health &

Human Services (HHS), (ii) the

federal Food and Drug Adminis-

tration (FDA), (iii) the National

Association of Pharmacy

Regulatory Authorities (NAPRA)

(Canada), (iv) in testimony

before the United States Con-

gress, and (v) through the

issuance of a Position Paper

(March, 2003); and

Whereas, a cooperative effort

between the state boards of

pharmacy, provincial authori-

ties of Canada, the Food and

Drug Administration (FDA),

and pharmaceutical manufac-

turers is the best means to

address this public health

concern;


NABP maintain its efforts to

eliminate this dangerous and

unlawful practice, continue to

support the efforts of the state

boards that are taking action

against the pharmacies and

facilitators involved in these

activities, and encourage the

FDA to continue its efforts to

enforce the existing laws on

importation and reimportation

of drugs; and

Be It Further Resolved that

NABP express its concern over

the effect that pricing policies

for pharmaceuticals are having

on the public health; and


NABP continue to work with

NAPRA and other entities to

address this issue and commu-

nicate with Canadian provin-

cial authorities in order to

obtain enforcement proceed-

ings in Canada to eliminate

this practice.

Resolution No. 99-6-03Title: Federal Regulation of

Nutritional Supplements Con-

taining Ephedrine Derivatives

Action: Passed

Whereas, over-the-counter

drugs that include ingredients

such as ephedrine, pseu-

doephedrine and phenylpro-

panolamine have been

identified as the current major

precursor chemicals used in

the illicit manufacture of

methamphetamine; and

Whereas, the Drug Enforce-

ment Administration (DEA)

and various states have taken

steps to restrict the quantities

of ephedrine, pseudoephedrine

and phenylpropanolamine that

may be purchased in a single

transaction; and

Whereas, these restrictions

have resulted in reducing the

availability of these drugs for

this illicit purpose; and

Whereas, the methamphet-

amine laboratories are turning

to nutritional supplements

containing ephedrine deriva-

tives (eg, ephedra, ma huang,

etc) as replacements;


NABP petition the DEA to add

nutritional supplement prod-

ucts containing ephedra to the

list of substances that are

subject to the control of the

Comprehensive Methamphet-

amine Control Act; and


NABP petition the DEA to

remove any exemptions that it

may have granted for ephe-

drine products containing

therapeutically significant

quantities of other active

medicinal ingredients.

Resolution No. 99-7-03Title: Continuing Pharmacy

Practice Competency

Action: Passed

Whereas, colleges, faculties,

and schools of pharmacy

educate and boards and

colleges of pharmacy license

pharmacists who are qualified

to provide “patient-centered

pharmacy care” to the public;

and

(continued from page 3)Meeting Delegates Approve Six Resolutions, Two Defeated


Whereas, the respect given to

and enjoyed by pharmacists

depends on pharmacists main-

taining their knowledge and

contemporary practice protocols

for various patient needs;


NABP endorse and encourage

structured programs of con-

tinuing professional develop-

ment; and


NABP encourage colleges,

faculties, and schools of

pharmacy and boards and

colleges of pharmacy to collabo-

rate on providing seminars to

further pharmacist continuing

professional development; and


the boards of pharmacy en-

courage, endorse, and support

the efforts of NABP, the Ameri-

can Council on Pharmaceutical

Education (ACPE), and the

American Association of

Colleges of Pharmacy (AACP) to

instill and perpetuate the

concepts of continuing profes-

sional development in students

and pharmacists.

Resolution No. 99-8-03Title: Recognition Resolutions

Action: Passed

Whereas, the individuals listed

here have made significant

contributions to NABP, the

protection of the public health,

and the profession of pharmacy:

n Lawrence “Larry”

Barker, Sr (WV)

n B. Belaire Bourg, Jr (LA)

n Lorna M. Freitas (GUAM)

n Malvin U. Goldstein (AL)

n Timothy Douglas

Moore (OH)

n Neil Pruitt (GA)

n John H. Smith (TN)

n Ken Smith (CO)

n John Street (AZ)

n Charles Thurgood (IN)

Whereas, NABP and its

member boards of pharmacy

are saddened by the death of

these individuals;


NABP and its members formally

acknowledge the leadership and

contributions made by these

individuals; and


NABP and the boards of

pharmacy extend their sincere

sympathies to the family and

friends of these members who

have died.

Resolution No. 99-1-03Title: Association Name Change

Action: Defeated

Whereas, the National Asso-

ciation of Boards of Pharmacy

(NABP) is a not-for-profit


Each year the NABP Execu-

tive Committee selects an

individual to serve as its

honorary president for the

coming year. NABP is pleased

to announce that John D.

Taylor, RPh, has been

granted this privilege for the

year 2003-2004.

In his present position as

drug inspector for Florida’s

Bureau of Statewide Phar-

maceutical Services, Taylor

is continuing his distin-

guished career in pharmacy

in the spirit of public

service that is essential to

the mission of NABP and

its member boards of

pharmacy. Before assuming

his current position, he

served as the executive

director of the Florida

Board of Pharmacy from

1990 to 2002.

Taylor’s service to NABP has

been filled with numerous

accomplishments. He has

John D. Taylor Named 2003-2004Honorary President

participated in many task

forces including the 2002

Task Force on the Evaluation

and Modification of NABP’s

Constitution and Bylaws; the

2001 Task Force on Privacy

and Confidentiality; the 2000

Task Force on Drug Diver-

sion through Institutional

Outlets; the 1999 Task Force

to Examine the Quality and

Standards of Internship

Requirements; the 1998 Task

Force on Regulating Patient

Outcomes; and on the 1997

and 1995 Task Forces on

Workload Systems.

NABP is not the only organi-

zation to recognize Taylor. He

is a two-time winner of the

University of Florida College

of Pharmacy’s Distinguished

Service Pharmacy Alumnus

Award, receiving that award

in both 2001 and 1999. Also,

in 2000, he was presented

with the Gamma Sigma

Chapter Kappa Psi Alumni

Recognition Award.


Good afternoon.

Last year in

Arizona as we

discussed,

debated, and

joined together

as members of

NABP, the

concern over

what the future would bring

and how our individual lives

and the comfortable world of

pharmacy regulation would be

impacted was ever present. On

those sunny days in Arizona,

despite the unimaginable

horror of 9/11, few would have

forecasted that a year later we

would plan our daily lives

according to the colored danger

level of the Homeland Security

warning chart or that the US

would have waged a successful

war against Iraq to keep us safe

from the atrocities of terrorists.

One year later, we have sur-

vived. In fact, we have forged

ahead as Americans, members

of boards of pharmacy, and

members of NABP. A year later

we stand together in Philadel-

phia celebrating a city rich in

American history and quietly

acknowledging the struggles

and victories that make the US

the land of the free and home

of the brave.

Importation of ForeignMedicationsAmidst the dramatic struggles

of the world, it is important to

keep our focus on our responsi-

bilities to protect the public

health. Yes, even though these

Report of the Executive Directorresponsibilities may seem to

pale in importance compared to

the life and death battles of

our troops, there is a certain

significance to what you do as

boards of pharmacy that

contributes to the final and

ultimate goal of keeping

America strong and free. How

ironic, amidst the interna-

tional conflicts we now face,

that one of the issues that

consumed most of our time

and efforts over the past year is

the importation of foreign

medications. The issue is

everywhere – in the media, in

the pharmacies we regulate,

and in the minds of countless

US citizens. I am pleased to

report that NABP has been at

the forefront of this issue and

taken an unequivocal stand.

Few people can dispute that

the current pricing policy for

pharmaceuticals is at the core

of the quandary. It is the force

driving US citizens to foreign

sources where prices are under

government control and

significantly less than in the

United States. NABP and

boards of pharmacy have

historically avoided any

involvement in pricing or

economic issues that appeared

to have little or no relevance to

the protection of the public

health. Although that ratio-

nale is sound and guides the

extent to which we can become

involved in the importation

debate, the public health

dangers caused by the impor-

tation of medications from

foreign sources are increasing

and not being resolved by

actions which seem to address

the symptoms of the problem.

If at this time we cannot direct

our efforts to the cause of the

dilemma, then for NABP and

the state boards of pharmacy

our priorities must focus on

managing other areas where

the public health is being

impacted. However, if the

problem worsens and the

health and safety of the public

further threatened, then NABP

and the state boards of phar-

macy may need to become

involved in the causes, even

though the causes for the

present state of affairs is

pricing, an area traditionally

labeled as outside the realm of

NABP and the state boards of

pharmacy. It appears that we

have little other choice because

the scope of this problem grows

exponentially each day. Data

recently received by NABP

indicates that, on average,

cross-border sales represent as

much as 3.5% of Canadian

sales. Simply computing this

percentage to project the value

of medications distributed at

the Canadian level places

cross-border shipments at

approximately $642 million for

2002, which translates into

$409 million US dollars! The

numbers are simply staggering;

nearly half a billion dollars for

2002 and growing at leaps and

bounds in 2003. The situation

now extends well beyond the

field trips of senior citizens to

Canada to purchase a few

medications. Sales and activity

in this area far exceed the

operations of many legitimate

business and industries

operating between Canada and

the United States.

Presented by NABP

Executive Director/Secretary

Carmen A. Catizone


The Executive Committee was

actively involved in this issue

before it became popular to do

so and before other groups

decided it was time to weigh in.

Responding to calls from the

individual states, various

districts, and MALTAGON, we

have been working with the

Food and Drug Administration

(FDA) and our colleagues in

the National Association of

Pharmacy Regulatory Authori-

ties (NAPRA) to combat this

problem. Our efforts have

included serving as a central

clearinghouse for information

on the activities of these illegal

enterprises, bringing our

message to the media loud and

clear, challenging legislators

who support these illegal

activities, and coordinating

enforcement activities between

the states and FDA. The

position paper that we recently

released provides the legal

basis for our position and

chronicles the enforcement

activities of the states and FDA

to date so as not to leave any

doubts that this is a serious

public health concern.

The policy which NABP is

advocating on your behalf is

clear: The importation of

unapproved medications is

illegal and the shipment of

medications into the majority

of states by pharmacies or

wholesale distributors not

licensed or registered in those

states is illegal. This being the

case, then the laws deeming

these activities illegal must be

enforced. If, however, the laws

cannot be enforced or do not

protect the public health and

welfare but simply serve as a

means to enhance the eco-

nomic standing of a particular

entity, then the laws must be

changed. If the laws need to be

changed, then those changes

should provide for the mutual

recognition of medications

between the FDA and Canada’s

comparable drug approval

agency and require that

Canadian pharmacists and

pharmacies license and/or

register with US boards of

pharmacy so as to comply with

the appropriate laws and

regulations. Rest assured that

we will continue to advocate

this position and represent the

interests of the boards of

pharmacy and the protection of

the public health despite

sustained counter efforts by

politicians locally and in

Washington, DC.

Compounding andNABP’s Changing RoleAnother area that has captured

our attention over the past

year is the age-old question of

compounding. In thinking

about what our reports should

detail this year, someone

suggested that in order to save

time and effort we simply

change the date on last year’s

reports. For pharmacy, that

idea is not all that bad because

some issues seem to stay

around forever. Compounding

is certainly one of those issues.

In 1997, FDA’s Modernization

Act amended the Food, Drug,

and Cosmetic Act and, among

other provisions, added section

503A on pharmacy compound-

ing. This section provided

federal parameters distinguish-

ing manufacturing from the

practice of pharmacy com-

pounding, including describing

who could compound, the

acceptable components for

compounding, the practices for

interstate commerce, and

restrictions on advertising. In

April 2002, the Supreme Court

struck down the law as uncon-

stitutional due to the advertis-

ing restrictions.

When the Supreme Court

struck down FDA’s 1997

provisions, it created a void in

the regulation of pharmacy

compounding. NABP has been

working with the FDA and

other pharmacy groups to

address this void and develop a

regulatory framework that

recognizes the need and legality

of pharmacists to compound

and separates compounding

continued on page 18

The policy which NABP isadvocating on your behalfis clear: The importation ofun-approved medicationsis illegal and the shipmentof medications into themajority of states bypharmacies or wholesaledistributors not licensedor registered in thosestates is illegal.

– NABP ExecutiveDirector/Secretary

Carmen A. Catizone


from manufacturing. Having

said that and admitting the

challenge of distinguishing

compounding from manufac-

turing, please be assured that

at least one of the reports

delivered by the Executive

Committee at the 2004 Annual

Meeting will probably include a

discussion on compounding.

And reports in 2005 and. . . .

However, in order to develop a

sound regulatory framework for

compounding, certain param-

eters must be established and

enforceable standards defined.

Clearly, the first step in this

process is distinguishing

between compounding and

manufacturing. This year’s

Committee on Law Enforce-

ment and Legislation is propos-

ing definitions to distinguish

between these two activities.

Their recommendations will be

reviewed by the Executive

Committee and a final recom-

mendation communicated to

the boards and all interested

parties. Once this Herculean

task is accomplished, the other

components of the regulatory

framework should fall nicely

into place. Those other compo-

nents must take into account

the importance of pharmacist

compounding, the understand-

ing that not all pharmacists

are qualified to compound all

products, and the acceptance

that quality assurance con-

trols must be in place to

ensure the integrity of com-

pounded products.

NABP will continue its present

efforts to define the differences

between compounding and

manufacturing and develop

educational and enforcement

tools to assist you in regulating

this growing area of pharmacy

practice. The Executive Com-

mittee is also pursuing other

means that may provide

additional assistance and

support to you in regulating

pharmacy compounding and

other key components of

pharmacy practice. NABP

recognizes that the economic

conditions in the states and

drain of resources are having a

devastating effect on the

budgets of the state boards of

pharmacy. Travel and other

board activities are being

severely limited and curtailed

as a drastic measure to reduce

billion dollar deficits. Simulta-

neously, boards of pharmacy

are being held responsible for

monitoring and regulating the

delivery of evolving pharmacist

services, the expanded role of

the technician, and the intro-

duction of more complicated

and dangerous medications,

which require increased vigi-

lance and monitoring. The

impending collision of these two

opposite forces makes the Big

Bang Theory a phenomenon

that those of us who missed it

the first time may be able to

experience in the near future.

As NABP works through this

crisis with you we are trying to

develop unique solutions to the

compounding issue as well as

the larger issue of diminished

resources and increased

responsibilities of the state

boards of pharmacy. Our

Verified Internet Pharmacy

Practice Sites™ (VIPPS®) pro-

gram has taught us how NABP

can serve as a valuable support

system for the states and offer

to you inspection services,

practice data monitoring and

sharing, and other activities

currently performed by the

board but impacted by budget

or resource cuts. The magnifi-

cence of the VIPPS program is

that it allows state boards of

pharmacy to oversee and

regulate the activities of

Internet pharmacies, within or

outside of their borders,

without expending valuable

resources. The Executive

Committee believes that the

VIPPS model can be employed

in other areas to assist the

state boards of pharmacy in

monitoring practice and

gathering critical data.

It is our intent to expand the

VIPPS model into other areas

that you and the Executive

Committee deem appropriate,

thus allowing NABP to serve as

an accrediting resource for you

and provide you with regular

reports and critical data on

the practices and outcomes of

pharmacists and pharmacies

under your jurisdiction. We

believe NABP can provide this

service to the states at little or

no cost and improve the

abilities of the state boards of

pharmacy to regulate pharma-

cists and pharmacies and

advance the protection of the

public health. Compounding

would appear to be a good area

to pilot such a system and

determine how NABP can help

the states to develop and

implement a new regulatory

framework. As the year moves

forward, more information

will be forthcoming as we

seek your input and coopera-

tion for this effort.

Report of the Executive Director(continued from page 17)


NABP in the Next 100 YearsAs we stand on the brink of our

100th Anniversary, and try to

foresee what the future will

hold, a magic crystal ball to

help us know what direction to

take, what decisions to make,

and where our lives are heading

would be invaluable. Our

themes for this year and the

100th Annual Meeting focus on

Continuing Professional

Development (CPD). As you

heard from President Fiacco’s

report, this is a project that

the Executive Committee is

extremely excited about and

has the potential to signifi-

cantly change pharmacists’

educational activities and their

scope of practice. The CPD

Project will undoubtedly occupy

a large portion of our agenda

during the first years of NABP’s

next 100 years. Hopefully, the

CPD Project in its examination

of continuing education and

what tools pharmacists require

to remain current and effective

in their practices will teach us

to approach pharmacy’s age-old

problems without the bias and

blinders of the past, but with

the openness and enthusiasm

of a promising future and

opportunity.

It is that enthusiasm and

unrestricted vision that will

characterize NABP in the next

100 years. NABP has to ap-

proach the future in that way

because we know that the

problems facing the boards of

pharmacy will not lessen while

the resources provided to you

to answer those problems will

lessen. It is a challenge that we

readily accept because if the

past 100 years have taught us

anything, it is that the

strength of the boards of

pharmacy unified through

NABP is a force with limitless

potential. As we celebrate this

99th Annual Meeting of the

National Association of Boards

of Pharmacy and prepare for

the 100th Annual Meeting, let

us look to each other for

strength, wisdom, and guid-

ance. Let us leave Philadelphia,

the site of the First Continen-

tal Congress and the begin-

nings of the American

Government as we know it

today, with the inspiration to

make a difference in the days,

months, and years ahead and

to keep the public health

paramount in our efforts and

goals. Let us leave this meeting

as colleagues within NABP

committed to helping our

Association flourish and grow

as the voice and embodiment of

the individual state boards of

pharmacy. Thank you.

corporation recognized by the

Internal Revenue Service as a

charitable and educational

organization [Section

501(C)(3)]; and

Whereas, the purpose of NABP

to assist the state boards of

pharmacy in protecting the

public health distinguishes

NABP from other pharmacy

associations; and

Whereas, the use of the word

“association” in NABP’s name

often creates the perception

that NABP is a trade or eco-

nomic group and leads certain

governmental bodies and the

public to miscategorize NABP

with other national pharmacy

organizations;


the Executive Committee study

the feasibility of NABP chang-

ing its name.

Resolution No. 99-2-03Title: Mandatory Continuing

Education on Medication Safety

Action: Defeated

Whereas, an important

responsibility of pharmacists

is assuring the safe use of

medications;

Meeting Delegates Approve Six ResolutionsTherefore Be It Resolved that

NABP work with the American

Council on Pharmaceutical

Education (ACPE), American

Association of Colleges of

Pharmacy (AACP), and colleges

and schools of pharmacy to

include medication safety as a

subject in the required curricu-

lum; and


NABP encourage its member

boards of pharmacy to require,

for license renewal, the comple-

tion of a minimum of two (2)

hours of continuing education

programming on the topic of

medication safety.



NABP’s 99th Annual Meeting Educational Presentation Area

The first-ever Poster Session, located in the Educational Presentation Area, featured displays of states’important issues. Pictured below are Dennis K. McAllister (left), vice president of the Arizona State Boardof Pharmacy. Pictured right, attendees discuss products with a representative from TelepharmacySolutions, Inc.

Above, representatives of ScriptPro perform a demonstration (left) for Educational Presentation Area visitors.Meeting attendees discuss pharmacy technology at the PDX-NHIN-RX.Com booth (right).

Ateb, Inc

Food and Drug Administration

Gold Standard Multimedia

McKesson APS

PDX-NHIN-RX.Com

Educational Presenters at NABP’s 99th Annual MeetingPharmacists Mutual Companies

PMC Quality Commitment, Inc

Pre-NAPLEX™

ScriptPro

Telepharmacy Solutions, Inc


NABP’s 99th Annual Meeting Educational Sessions

Annual Meeting Educational GrantsNABP gratefully acknowledges the following pharmaceutical companies and organizations whose

educational grants to the NABP Foundation have contributed to the success of the Association’s

99th Annual Meeting.

Abbott Laboratories

Albertson’s, Inc

AstraZeneca Pharmaceuticals Group

Barr Laboratories

Cardinal Health

Chauncey Group International

Eckerd Corporation Foundation

Eli Lilly & Company

Hoffman LaRoche Service Corporation

GlaxoSmithKline

Medco Health Solutions, Inc

Merck & Co, Inc

Ortho-McNeil Pharmaceutical

Pfizer US Pharmaceuticals

Prometric

Purdue Pharma, LP

Walgreen Company

Dale J. Atkinson (upper left), counsel from Atkinson &Atkinson, speaks to Annual Meeting attendees aboutrecent regulatory cases. Well-attended continuingeducation sessions covered topics ranging frommedication error data review to substance abusetreatment.


patient care is not having

access to information that

allows us to provide appropri-

ate counseling, education, and

monitoring. The health care

system needs to address this

troubling deficiency within the

constraints of the privacy rules

and give pharmacists access to

vital patient information.

Pharmacists must have this

information to ensure patient

safety. As president, I will urge

the Executive Committee to

continue its dialogue with other

health care practitioner groups

to support the mandating of

medication indications on

prescriptions and drug orders.

I know that many of you have

fought this fight before and can

offer an endless number of

reasons as to why it will not

move forward. Some of the

reasons that have stalled this

effort in the past are patient

privacy, increased burden on

the prescriber’s time, or denial

of reimbursement from insur-

ance companies if the drug is

used for a non-Food and Drug

Administration (FDA) approved

indication. These issues,

however, can be overcome. The

Institute for Safe Medication

Practices (ISMP) has promoted

the idea of including the

medication indication on the

prescription and drug order for

years. In fact, pharmacy is not

the only health profession

seeking this change. Nurses in

hospitals, nursing homes, and

home health care settings are

looking for the inclusion of

similar information on patient

orders. Physical therapists,

respiratory therapists, and

speech therapists are urging

Remarks of the Incoming Presidentthat more information about a

patient should be provided to

them to ensure the appropriate

and highest quality of care.

I’m sure many of you who have

fought this battle before me are

saying, “We agree, we’ve heard

this before, but we have not

seen the issue move beyond

pharmacy’s own discussions.

How can it work now?” I believe

that if boards mandate that

prescriptions or drug orders

include a medication indica-

tion line that must be com-

pleted by the prescriber in order

for the prescription or order to

be deemed legally valid, that

the problem can be addressed

effectively. Of course, there will

be situations where such

information should not be

disclosed and those situations

can be addressed by wording

such as “medically indicated

not to disclose.” As NABP

president, I will do my best to

move this item forward and

champion the Executive

Committee to work with the

other health care professionals.

Be assured, however, that the

pharmacist’s access to patient

information does not end with

indications, but that this is

the portal to create a tidal

wave of change.

What is also needed to improve

the communication of informa-

tion from prescriber to pharma-

cist, again as documented by

the findings of ISMP, is the

elimination of handwritten

prescriptions. Does it seem

plausible in today’s high tech

and sophisticated operating

system world that we allow

prescribers to handwrite vital

patient information in a

language of codes and outdated

symbols that few can remember

or translate? It is time to

improve the process by elimi-

nating another opportunity for

error by removing handwritten

prescriptions.

In order to accomplish this, I

believe it will require the

support of other medical

professionals. I am hopeful

that NABP will embrace this

idea and move forward to work

with the medical organizations

and other pharmacy associa-

tions to ensure its success.

Best Practices RegulationUnfortunately, much of our

time as boards and board

members is spent on the

problem areas of pharmacy. It

is very difficult for most of us

to get outside these bound-

aries. Yet, as board members

we are obligated to regulate all

areas of the profession, not

just those areas where disci-

pline results. As board mem-

bers, we also need to appreciate

that pharmacy is not just one

practice. Pharmacy practice is

comprised of a multitude of

different types of practice, each

of which is important to the

patients that rely on them for

care and safety. I would like to

hear from the practicing

pharmacists in their areas of

expertise. Quite frankly, I am

tired of regulating minimal

practice. Let’s hear from the

best of practitioners and their

best practices, let’s hear about

what they have accomplished

and how we incorporate “best

practices” into our regulations.

As president, I will propose a


continued on page 23


Representatives from the Food

and Drug Administration

(FDA) encouraged state boards

of pharmacy to contact that

agency when attempting to

combat storefront pharmacy

operations and Web sites that

are illegally importing drugs

from Canada and other

countries during the “Update

on the Importation of Foreign

Medications” session at

NABP’s 99th Annual Meeting,

held May 3-7, 2003, at the

Philadelphia Marriott Hotel in

Philadelphia, PA. FDA’s

William K. Hubbard, associate

commissioner for policy and

planning, and Thomas J.

McGinnis, director, pharmacy

affairs, took questions from

attendees during the session.

The illegal importation of

medications has many effects,

including undermining the

security of the United States’

drug supply, undermining the

confidence of regulatory

authorities, and undermining

the FDA’s ability to assure

FDA Solicits Boards’ Assistance to Fight Storefront Pharmacy Operationspeople that those drugs are

safe, says Hubbard.

“Our main message today is

that we really want to work with

each state to try to deal with

these cases in whatever coop-

erative way we can,” he says.

“We want to work with each one

of you to identify storefront

pharmacies or Web sites [selling

illegally imported drugs] in your

states so that we can sit down

together and decide which

regulatory strategy is best and

take joint action where our

individual laws do work.”

Although Canada’s laws also

prohibit transshipment of

unapproved drugs, FDA is

concerned that recent state-

ments by Health Canada (a

federal health agency) about the

safety of drugs in that country

will be construed as assurance

that the drugs being sold over

the Internet are safe, further

encouraging American consum-

ers to buy drugs from Canada.

McGinnis notes that a letter to

the Kullman Firm in New

Orleans, LA, outlines which

parts of the Federal Food,

Drug, and Cosmetic Act are

being violated by storefront

operations and Web sites, and

that the full letter can be

found on FDA’s Web site at

www.fda.gov/ora/import/

kullman.htm.

“We still need your help,”

McGinnis says. “We need any type

of adverse events, medication

mix-ups, [or] medication errors

that are occurring not only from

pharmacies shipping to the US

from Canada, but from anyplace

else in the world.”

Currently, there are 113 Web

sites advertising drugs from

Canada as well as many more

sites from other sources

around the world. McGinnis

adds that by the end of 2003,

$1.4 billion in prescription

drugs will be coming out of

Canada into the US, represent-

ing 10% of Canada’s pharma-

ceutical sales. This is up from

$700 million in prescription

imports coming in to the US

in 2001.

session on best practices at

one of our upcoming meet-

ings or educational confer-

ences so that the lessons

learned from those sessions

can be incorporated into

state regulations. These

lessons and NABP’s regulat-

ing for outcomes focus can

certainly make a difference

and place our focus on

helping pharmacists provide

the best care to their pa-

tients. I know that I have set

Remarks of the Incoming Presidentan aggressive, challenging, and

different agenda for the upcom-

ing year. However, I am pas-

sionate about these issues and

the patients I serve. I also

believe that I am not alone in

these thoughts. This organi-

zation is heading into its

100th year of existence. We

will celebrate this monumen-

tal milestone next year in

Chicago. At that 100th Anni-

versary Celebration, we will

acknowledge that in all the

past 100 years, NABP’s focus

has always remained on the

safety of the patient.

As your president, I want to

thank you for the faith you

have shown in me to lead this

organization and I will do my

best to serve this organization

and its membership. Be

assured, however, under my

leadership NABP will aggres-

sively continue its pursuit of

patient care and safety.



(continued on next page)

services will be dramatic and

cutting edge. The implementa-

tion time line for this project is

in place and changes in some

of NABP’s programs and the

data available to the state

boards of pharmacy should

begin to be available by the end

of this year.

Continuing ProfessionalDevelopmentAs I close out my year as

president, I am grateful for the

support of the Executive

Committee and each of you. It

has been a busy year and

although not everything I

wanted to accomplish has been

accomplished, it has been a

good year and we have made

significant forward progress. I

am most excited about NABP’s

newest project, Continuing

Professional Development. This

is a hallmark project that has

the potential to redefine some

of the basic tenets of pharmacy

and support all of those

patient care services that the

profession of pharmacy has

been discussing since before

Remington sat in his chair at

the American Pharmacists

Association headquarters! You

will hear more about this

exciting initiative in a presen-

tation on Monday from Peter

Vlasses, executive director of

the American Council on

Pharmaceutical Education, and

Avery Spunt, NABP’s compe-

tency assessment director.

The first phase of the Continu-

ing Professional Development

project will be NABP’s offering

of an Internet based self-

assessment mechanism. This

self-assessment instrument

combines all of the expertise

NABP has developed in other

areas with our recent Internet

testing experience to offer

pharmacists the opportunity to

assess their needs and inter-

ests in a non-challenging and

supportive environment. The

next phases of the project,

which involve collaboration

with virtually every organiza-

tion in pharmacy, will provide

continuing education resources

and portfolio design and

management strategies that

will help pharmacists change

their practices to effectively

serve as their patients’ medica-

tion adviser. It is a bold

challenge and a bolder initia-

tive. However, it is one that is

necessary and whose time has

finally come.

What has me most excited

about this project is the open

collaboration that is occurring

between NABP and the other

pharmacy groups. In our

discussions with other phar-

macy groups, the sentiment is

the same: “We hear the mes-

sage and we are on board.” The

responses from the other

organizations have also

included the sage advice to

nurture this project through

with patience, sensitivity to the

concerns of practitioners, and

determination. The time for

“wait and see” has passed and

the time for action is now with

us. It is a good project for

pharmacy, for NABP, for

pharmacists, and, most

importantly, for the patients

we serve. You can be sure that

more information about this

historic project will be forth-

coming in the NABP Newsletter

and other NABP communica-

tions. I am pleased to an-

nounce that the Executive

Committee and NAPRA have

drafted a position statement

whereby NAPRA and NABP

pledge to work together to

protect the citizens each are

mandated to serve and to

promote compliance with the

federal, state, and provincial

laws and standards of Canada

and the United States, to

ensure the safety and integrity

of the prescribing drug supply

in their respective jurisdictions.

As my term ends, I can say

with confidence that the

Association is strong and well

positioned for the future. From

an Association perspective, the

one thing that was most

noticeable during my travels

was what I shall call the

changing of the guard. The

faces that make up NABP have

changed considerably over the

past 10 years of my involve-

President’s Address(continued from page 7)

“[Continuing ProfessionalDevelopment] is a hallmarkproject that has thepotential to redefine someof the basic tenets ofpharmacy and support allof those patient careservices that the pro-fession of pharmacy hasbeen discussing. . . .”

– NABP 2002-2003President John A. Fiacco


Report of the Treasurer

ment. The new members of

the Association are the future

leaders and the future of

NABP. We are in good hands

and the future is bright.

Finally, I want to again thank

every one of you for giving me

the opportunity to serve as

your president. It was an

exciting year from many

perspectives. It was a year

that has passed so quickly.

I am very appreciative of the

support and friendship that

you have demonstrated at the

district meetings and over the

course of my presidency. The

experience is gratifying and

humbling. I also want to

publicly thank Carmen and

the staff of NABP for their

hard work and determination.

They are the backbone of

NABP and the main reason

for our continued growth and

success. I also want to thank

Carmen specifically for his

efforts on behalf on NABP. He

has crossed the country

many times meeting with

Congress, state leaders,

reporters, or other leaders of

pharmacy, often with little

notice. His efforts have been

very successful in moving

NABP to the forefront of

pharmacy. We are fortunate

to have Carmen at the helm.

It has been an honor and a

privilege to serve you.

Thank you again for that

opportunity.

President’s Address(continued from previous page)

These reserves represent 89% of

NABP’s 2003 operating budget,

ensuring NABP’s ability to

continue to provide the quality

services our members expect.

Now I would like to direct your

attention to the NABP Founda-

tion. Both the State Newsletter

Program and the NABPLAW®

Online pharmacy law database

operate within the NABP

Foundation. The Foundation is

the educational arm of the

Association that also oversees

our research and development

projects.

As Donna Wall mentioned last

year in her Treasurer’s Report,

we hoped to be able to report

an increase in Foundation

revenue due to moving

NABPLAW online and billing for

subscriptions every 12 months

rather than 18 months. We are

happy to announce that the

NABP Foundation saw a 35%

increase in NABPLAW revenue

over 2001. NABP continues to

offer NABPLAW Online to the

boards at a discounted rate.

The old 18-month renewal

cycle created inconsistent

revenue from year-to-year.

With the switch to NABPLAW

Online and a 12-month re-

newal cycle, we expect the

trend to be toward a consistent

revenue stream with annual

growth.

Of the 34 states that partici-

pate in the State Newsletter

Program, two states now

produce Web-only newsletters.

The benefit of the Web-only

option is the significant cost

savings to the boards. For

example, a state that prints

6,000 newsletters pays nearly

$9,000 per year for four issues,

but the same state could utilize

the Web-only option for a mere

$580 a year. A combination of

printed and online newsletters

is also an option for states that

require a printed newsletter be

housed in every pharmacy.

NABP staff would be happy to

talk with you to discuss the

options available to you.

Expenses incurred through the

newsletter program are reim-

bursed by the participating

boards.

NABP’s excellent financial

strength allows the Association

to provide a grant to the

Foundation earmarked for the

research and development of

new programs such as the Pre-

NAPLEX™ and Continuing

Professional Development

programs.

Our auditors, Culumber and

Scanlan, Ltd, found both NABP

and the NABP Foundation to be

in good financial order. They

commented on the overall

financial strength of both

organizations, which is evi-

denced in part by the ratio of

NABP’s Assets to Liabilities,

which is two to one. Our

auditors also noted that both

organizations appear to be well

positioned for the future. A copy

of this address, along with

NABP’s 2003 operating budget

and financial statements, will be

available at the registration

desk immediately following this

session. If you have any ques-

tions about NABP’s financial

position, please see Carmen

Catizone or me at any time

during this meeting. A copy

of the financial statement is

also avialable by contacting

NABP via e-mail at

[email protected]. It has

been a pleasure to serve as your

treasurer. Thank you.



Leaders Receive Honors at Awards Dinneron Law Enforcement/Legisla-

tion, the Bureau of Voluntary

Compliance in 1998, and the

Task Force on Workload

Systems in 1997. While a

Nebraska Board member,

Anderson was a member of the

Board’s Tripartite Pharmacy

Internship Committee, the

Pharmacy Practice Act Rewrite

Task Force, and the Pharmacy

Technician Task Force. In

addition, he has given his time

and talent to other profes-

sional associations like the

Nebraska Pharmacists Associa-

tion and the National Commu-

nity Pharmacists Association.

Timothy J. Benedict, NABP’s

second Lester E. Hosto Award

recipient, continues to demon-

strate his dedication to the

Association and his commit-

ment to ensuring that phar-

macy is practiced safely and

professionally while serving as

one of the original Verified

Internet Pharmacy Practice

Sites™ (VIPPS®) inspectors. He

has spent countless hours

performing inspections of

pharmacies that have applied

for the prestigious award of

VIPPS certification. As assis-

tant executive director of the

Ohio State Board of Pharmacy,

Benedict supervises the activi-

ties of field staff in inspections

of drug distributors and

investigations of illegal activi-

ties by health professionals

dealing with drugs; he assists

and coordinates the efforts of

federal, state, and local law

enforcement agencies in the

diversion of drugs; and aids

with the prosecution of health

professionals and cases for

action by licensing agencies.

Beginning as a pharmacy

consultant with the Ohio Board

in 1980, Benedict assumed the

position of assistant executive

director in 1998.

2003 Fred T. MahaffeyAwardThis year, NABP presented the

California State Board of

Pharmacy with the 2003 Fred

T. Mahaffey Award for its

dedication and commitment in

sponsoring legislation that

resulted in mandated quality

assurance programs for phar-

macies. In 2000, the Board

sponsored a bill that required

pharmacies to implement a

quality assurance program to

prevent prescription errors from

recurring and exempted quality

assurance documents from

discovery. Since the bill’s

implementation in California,

other states have begun similar

programs. NABP also com-

mended California for its

aggressive enforcement against

pharmacies for filling Internet

prescriptions for patients

without a “good-faith prior

medical examination.” In 2002,

the Board issued the largest

fines ever, totaling $87 million,

to a Los Angeles pharmacy and

two pharmacists for filling

more than 3,500 illegal

Internet prescriptions. John D.

Jones, president of the Califor-

nia State Board of Pharmacy,

accepted the award on the

Board’s behalf.

2003 Henry Cade IndustryAwardsNABP established the Henry

Cade Industry Award in

memory of NABP’s 1987-1988

president to honor those

individuals within the pharma-

ceutical industry who have

supported the goals and

objectives of the Association

and the state boards of phar-

macy to protect the public

health. This year NABP chose

three recipients: Abbott Labo-

ratories’ director for Profes-

sional Affairs, E. Scott

“Scotty” Bowman,

GlaxoSmithKline’s president of

US Pharmaceuticals, Christo-

pher Viehbacher, and

GlaxoSmithKline’s director of

Strategic Operations for State

Government Affairs, Jeff

Peterson.

Abbott Laboratories has

continually supported NABP

and the district meetings in

protecting the public health,

and Bowman recognizes the

value of partnering with the

boards of pharmacy given the

many regulatory issues associ-

ated with products he has

represented over the years. A

17-year pharmaceutical indus-

try veteran, Bowman’s career

includes the positions of sales

representative, district man-

ager, managed care executive,

regional manager of govern-

ment affairs, director of

government affairs, and now

the director of Professional

Affairs focusing on regulatory

and Medicaid issues. His

interest in health care law

prompted him to enroll in the

Seton Hall Law School masters

program, where, in 2001, he

received his master’s degree in

science and jurisprudence.

The other two recipients of the

Henry Cade Industry Award




tution and Bylaws. Substantive

amendments address expan-

sion of the EC from six to eight

members with one originating

from each district, candidate

eligibility requirements,

candidate nomination proce-

dures, and elimination of the

Nominating Committee. The

proposed changes also attempt

to more clearly define Active

and Associate membership

within NABP using participa-

tion in the NABP Clearing-

house Program as the basis for

the distinction in membership.

While all of the EC’s proposed

amendments to the Constitu-

tion along with the first set of

the Committee’s proposed

changes to the Bylaws will be

voted upon next year, the

remaining changes to the

Bylaws will be read today after

the vote on the Nevada pro-

posal this afternoon, and voted

on during the Second Business

Session tomorrow. These

amendments expand the basis

for licensure transfer beyond a

license by examination to

include a license earned

through the licensure transfer

process, provided certain

conditions have been met.

The final proposed changes to

be presented at this meeting

originate from the Committee

on Constitution and Bylaws

(CBL). The proposed amend-

ments submitted by this

Committee are identical to the

EC proposed amendments,

with two exceptions: the CBL’s

constitutional change reduces

the term of office for EC

members from three to two

years, and its Bylaws proposal

clarifies that accepting an

applicant for licensure through

the NABP Clearinghouse based

upon a license obtained by

licensure transfer, with certain

conditions satisfied, is optional

for member boards. The CBL’s

Constitutional proposal will be

voted on next year, while the

Bylaws proposal will be read

Report of Executive Committeelater this afternoon and voted

on tomorrow.

This is certainly an exciting

time for NABP. With the

expansion of the VIPPS program

and the changes to the Consti-

tution and Bylaws, NABP is

positioning itself for future

growth and stability for years to

come. But with great sadness

for me, this meeting marks the

last time that I will be address-

ing you as a member of the

Executive Committee. I can’t

tell you how much your support

and especially your friendship

has meant to me and my

family. As I mentioned earlier,

my daughter Karen’s regret at

not being able to attend this

final meeting for me as a

member of your Executive

Committee. My wife Ruth and I

will always cherish the memo-

ries of NABP and the friends we

have made. We thank each and

every one of you for those

memories. Thank you.

Leaders Receive Honors at Awards Dinnercome from GlaxoSmithKline, a

company committed to uphold-

ing the laws that protect the

public health. In light of the

recent drug importation issues

that pharmacists, drug manu-

facturers, and the public are

currently facing,

GlaxoSmithKline’s decision to

support regulators and refuse to

supply its medications to

Canadian wholesalers and

pharmacies that illegally export

to US patients is an excellent

illustration of

GlaxoSmithKline’s commitment

to upholding the laws that

protect the public health.

Viehbacher, president of

GlaxoSmithKline’s US Pharma-

ceuticals division, has been

with the company since 1988,

when it was known as Glaxo

Wellcome. He assumed his

current role in January 2003.

Prior to that time, Viehbacher

served as president of Pharma-

ceuticals Europe since 2001.

Also a recipient of the 2003

Henry Cade Industry Award,

Peterson has been the director

of Strategic Operations of State

Government Affairs since

December 1998. In this posi-

tion he is responsible for

GlaxoSmithKline sales to state

Medicaid programs, state AIDS

Drug Assistance Programs, and

other state assistance pro-

grams. He has been with Glaxo

since 1987, when he joined as

a sales representative.



NABP’s 99th Annual Meeting Highlights

Documents

Member Boards Experience Comradeship, Education at …a task force to study the public health consequences of re-stricted access policies and programs. Resolution No. 99-4-03 Title: